Peter M. Voorhees

Also affiliated with Wake Forest University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma”.

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

New England Journal of Medicine(2022)10.1056/nejmoa2204925

N/A

6.2DataRank · unranked

474 citations

Susanna Jacobus, Edie Weller, Hani Hassoun, Sagar Lonial, Noopur Raje +51 more

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30354-9

N/A

3.8DataRank · unranked

126 citations

Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Sandi Hita +12 more

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Leukemia(2020)10.1038/s41375-020-0718-z

N/A

2.9DataRank · unranked

98 citations

Ajai Chari, Yaël C. Cohen, Andrew Spencer, Peter M. Voorhees, Jane Estell +16 more

A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)

American Journal of Hematology(2021)10.1002/ajh.26361

N/A

0.994DataRank · unranked

23 citations

Vera J. Suman, Sascha A. Tuchman, Jacob P. Laubach, Hani Hassoun, Yvonne A. Efebera +7 more

Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8507

N/A

0.494DataRank · unranked

26 citations

Sikander Ailawadhi, Rachael Sexton, Antje Hoering, Brea Lipe, Sandi Hita +9 more

Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse

Blood Advances(2024)10.1182/bloodadvances.2024013623

N/A

0.372DataRank · unranked

5 citations

Vera J. Suman, Yvonne A. Efebera, Noopur Raje, Sascha A. Tuchman, Cesar Rodriguez Valdes +7 more

Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.8054

N/A

0.241DataRank · unranked

4 citations

Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Jason Valent +11 more

Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death

UNC Libraries(2020)10.17615/f9gy-gn57

N/A

0DataRank · unranked

0 citations

Peter M. Voorhees, Robert Z. Orlowski, Deborah J. Kuhn, George W. Small, Jeffrey A. Nemeth +2 more

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

UNC Libraries(2020)10.17615/tpk1-js83

N/A

0DataRank · unranked

0 citations

Deborah J. Kuhn, Robert Z. Orlowski, Valeria Magarotto, Mark Cornfeld, Michael Wang +8 more

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

UNC Libraries(2020)10.17615/tmgg-w910

N/A

0DataRank · unranked

0 citations

Suzanne Lentzsch, Pieter Sonneveld, Sonja Zweegman, Hong Xie, Xiang Qin +13 more

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

UNC Libraries(2020)10.17615/tfn8-cp59

N/A

0DataRank · unranked

0 citations

Ming Qi, Peter M. Voorhees, Frits van Rhee, Razelle Kurzrock, Luis Fayad +5 more

Data from Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma

(2023)10.1158/1078-0432.c.6516807.v1

N/A

0DataRank · unranked

0 citations

Qing Chen, Deborah J. Kuhn, George W. Small, Sally A. Hunsucker, John S. Strader +5 more

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

UNC Libraries(2020)10.17615/q2fj-2t55

N/A

0DataRank · unranked

0 citations

Flora Mulkey, Robert Z. Orlowski, Ben L. Sanford, Richard A. Larson, Susan M. Geyer +5 more

Enzymatic cleavage of uracil-containing single-stranded DNA linkers for the efficient release of affinity-selected circulating tumor cells

UNC Libraries(2020)10.17615/35kw-cf72

N/A

0DataRank · unranked

0 citations

Paola A. Gehrig, Weiya Z. Wysham, Paul M. Armistead, Victoria Bae‐Jump, Peter M. Voorhees +9 more